Back to News
No items found.
We are proud to share that VitalTrace has been awarded $500,000 as part of the Government of Western Australia’s Future Health Research and Innovation (FHRI) Fund’s Innovative Solutions – Precision Health program.
VitalTrace is poised to revolutionise childbirth with DelivAssure, following our world-first clinical trial (read about it here.
This recent grant win allows us to extend our impact beyond childbirth and into a baby’s first days of life. Our continuous lactate monitoring (CLM) technology will be adapted to detect elevated lactate in neonates, an early indicator of neonatal sepsis, which has a mortality rate of 17-25%.
Lactate is a vital biomarker of metabolic stress, rising in not only sepsis, but other serious complications such as congenital heart disease and necrotising enterocolitis.
With our CLM technology, clinicians could gain real-time and accurate insights into neonatal wellbeing without repeated heel pricks or blood draws, facilitating early diagnosis, better management and reducing pain, trauma and blood loss in critically ill newborns.
Thank you to the FHRI for supporting our mission to significantly improve newborn outcomes and drive precision health innovation in Western Australia.
See the announcement here.
No items found.
No items found.
VitalTrace receives government backing for local manufacturing
VitalTrace is proud to announce it has received support from the McGowan government, Roger Cook and Medical Technology and Pharmaceutical (MTP) Connect under the WA Life Sciences Innovation Hub Manufacturing Voucher Program.
November 4, 2021
•
3 min read
VitalTrace is proud to announce it has received support from the McGowan government, Roger Cook and Medical Technology and Pharmaceutical (MTP) Connect under the WA Life Sciences Innovation Hub Manufacturing Voucher Program.
MTPConnect Managing Director and CEO, Dr Dan Grant, said, “Manufacturing medical products is a national priority so we’re supporting these promising projects to develop their medical devices and diagnostics.”
The MTP initiative, driven by Tracey Wilkinson and Kevin Pfleger, aims to accelerate the development and manufacturing of medical technology and pharmaceutical products in WA, such as medical devices, diagnostics, biologics and pharmaceuticals. The program is currently co-funded through the McGowan Government's New Industries Fund, industry growth centre MTPConnect and The University of Western Australia.
VitalTrace is honoured to be one of five WA-based companies under the scheme to been awarded a total of $450,000 to accelerate innovation projects requiring advanced manufacturing capabilities.
VitalTrace’s Chief Executive Officer said, “We are so fortunate to be supported by the McGowan Government through MTPConnect. This will not only bolster our path to market, but also bring new opportunities for Western Australia.”
This wonderful news adds to recent announcement of a new fund of approximately $40 million of ongoing support made towards health and medical research, innovation and commercialisation in Western Australia by Roger Cook.
No items found.
VitalTrace's first peer-reviewed journal article published in The SMFM Pregnancy Journal
Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.
June 6, 2025
•
3 min read
Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.
In collaboration with The University of Western Australia, our study demonstrates the capability of our technology, DelivAssure, in detecting early signs of fetal lactic acidosis, highlighted by the strong correlation between sensor current and venous blood lactate levels.
We're proud to contribute to the growing body of evidence aimed at improving outcomes for mothers and babies — DelivAssure has the potential to revolutionise intrapartum care by enabling crucial early detection and management of fetal asphyxia during labor and delivery.
📰 Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/pmf2.70017
We're incredibly grateful to our collaborators, clinical partners, and the SMFM editorial team for supporting this work.
No items found.
VitalTrace presents pre-clinical data at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting
Prof. Jonathan Morris, Chief Medical Officer, presents VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado.
January 28, 2025
•
3 min read
From Prof. Jonathan Morris, VitalTrace - Chief Medical Officer
I had the wonderful opportunity to present VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado. This is the premier pregnancy meeting in USA. Our abstract was one of the 104 selected for presentation out of more than 2,000 submitted speaking to the significance and magnitude of the accomplishments we have achieved.
SMFM was a great opportunity to connect with obstetricians allowing VitalTrace to build invaluable relationships with leading practitioners and forming alliances to prepare the company for future activity in the United States and beyond. There was very strong interest in DelivAssure from leaders in Boston, Washington, Texas, East Virginia, New York and Philadelphia amongst others.
Some particularly notable feedback:
From Dr Emily Reiff (Brigham and Women’s Hospital, Harvard Medical School),
“I was fascinated by your study of real-time fetal lactate monitoring and think that innovation like this is what is needed for effective intrapartum management.”
From Dr Justin Lappen (Cleveland Clinic),
“The whole team thought that DelivAssure would assist with Class II CTG dilemmas.”
It was reinvigorating to see such strong support for continuous lactate monitoring and reinforces our confidence to launch DelivAssure in the United States.